The effectiveness and safety of amisulpride in Chinese patients with schizophrenia who switch from risperidone or olanzapine: a subgroup analysis of the ESCAPE study

Ying Liang, Xin Yu On behalf of the ESCAPE Study Group Peking University Sixth Hospital, Peking University Institute of Mental Health, Key Laboratory of Mental Health, Ministry of Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital),...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Liang Y, Yu X
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	schizophrenia amisulpride risperidone olanzapine China Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/9123e28ac8cd4abca0e9426817d86ee4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9123e28ac8cd4abca0e9426817d86ee4
record_format	dspace
spelling	oai:doaj.org-article:9123e28ac8cd4abca0e9426817d86ee42021-12-02T04:00:23ZThe effectiveness and safety of amisulpride in Chinese patients with schizophrenia who switch from risperidone or olanzapine: a subgroup analysis of the ESCAPE study1178-2021https://doaj.org/article/9123e28ac8cd4abca0e9426817d86ee42017-04-01T00:00:00Zhttps://www.dovepress.com/the-effectiveness-and-safety-of-amisulpride-in-chinese-patients-with-s-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Ying Liang, Xin Yu On behalf of the ESCAPE Study Group Peking University Sixth Hospital, Peking University Institute of Mental Health, Key Laboratory of Mental Health, Ministry of Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, People’s Republic of China Introduction: Second-generation antipsychotics show significant interpatient variability in treatment response and side-effect profiles, and the majority of patients with schizophrenia require multiple treatment changes. This subgroup analysis of the ESCAPE study evaluated the efficacy and safety of amisulpride in Chinese patients with schizophrenia who switched from risperidone or olanzapine.Methods: ESCAPE was a prospective, open-label, multicenter, single-arm Phase IV study in which Chinese patients with an ICD-10 diagnosis of schizophrenia received amisulpride for 8 weeks. This analysis included 109 patients who switched to amisulpride from risperidone (n=68) or olanzapine (n=41) and 59 treatment-naïve patients for reference. The primary effectiveness outcome was a ≥50% decrease in Positive and Negative Syndrome Scale (PANSS) Total score from Baseline to Week 8. The study was registered at ClinicalTrials.gov (NCT01795183).Results: Of the patients who switched from risperidone and olanzapine, 77.9% and 56.1% achieved ≥50% reduction in PANSS Total score from Baseline to Week 8 and 57.4% and 46.3% achieved ≥20% reduction in PANSS score from Baseline to Week 2, respectively; these end points were achieved by 66.1% and 61.0% of treatment-naïve patients, respectively. No unexpected adverse events (AEs) were reported. Of the most common AEs, extrapyramidal side effects occurred in 32.4% and 14.6%, blood prolactin increase in 32.4% and 39.0%, and ≥7% increase in body weight in 4.4% and 12% of patients switching from risperidone and olanzapine, respectively.Conclusion: The results of this subgroup analysis suggest that switching to amisulpride from risperidone and olanzapine is effective and generally well tolerated in Chinese patients with schizophrenia. Keywords: schizophrenia, amisulpride, risperidone, olanzapine, ChinaLiang YYu XDove Medical PressarticleschizophreniaamisulpriderisperidoneolanzapineChinaNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 13, Pp 1163-1173 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	schizophrenia amisulpride risperidone olanzapine China Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	schizophrenia amisulpride risperidone olanzapine China Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Liang Y Yu X The effectiveness and safety of amisulpride in Chinese patients with schizophrenia who switch from risperidone or olanzapine: a subgroup analysis of the ESCAPE study
description	Ying Liang, Xin Yu On behalf of the ESCAPE Study Group Peking University Sixth Hospital, Peking University Institute of Mental Health, Key Laboratory of Mental Health, Ministry of Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, People’s Republic of China Introduction: Second-generation antipsychotics show significant interpatient variability in treatment response and side-effect profiles, and the majority of patients with schizophrenia require multiple treatment changes. This subgroup analysis of the ESCAPE study evaluated the efficacy and safety of amisulpride in Chinese patients with schizophrenia who switched from risperidone or olanzapine.Methods: ESCAPE was a prospective, open-label, multicenter, single-arm Phase IV study in which Chinese patients with an ICD-10 diagnosis of schizophrenia received amisulpride for 8 weeks. This analysis included 109 patients who switched to amisulpride from risperidone (n=68) or olanzapine (n=41) and 59 treatment-naïve patients for reference. The primary effectiveness outcome was a ≥50% decrease in Positive and Negative Syndrome Scale (PANSS) Total score from Baseline to Week 8. The study was registered at ClinicalTrials.gov (NCT01795183).Results: Of the patients who switched from risperidone and olanzapine, 77.9% and 56.1% achieved ≥50% reduction in PANSS Total score from Baseline to Week 8 and 57.4% and 46.3% achieved ≥20% reduction in PANSS score from Baseline to Week 2, respectively; these end points were achieved by 66.1% and 61.0% of treatment-naïve patients, respectively. No unexpected adverse events (AEs) were reported. Of the most common AEs, extrapyramidal side effects occurred in 32.4% and 14.6%, blood prolactin increase in 32.4% and 39.0%, and ≥7% increase in body weight in 4.4% and 12% of patients switching from risperidone and olanzapine, respectively.Conclusion: The results of this subgroup analysis suggest that switching to amisulpride from risperidone and olanzapine is effective and generally well tolerated in Chinese patients with schizophrenia. Keywords: schizophrenia, amisulpride, risperidone, olanzapine, China
format	article
author	Liang Y Yu X
author_facet	Liang Y Yu X
author_sort	Liang Y
title	The effectiveness and safety of amisulpride in Chinese patients with schizophrenia who switch from risperidone or olanzapine: a subgroup analysis of the ESCAPE study
title_short	The effectiveness and safety of amisulpride in Chinese patients with schizophrenia who switch from risperidone or olanzapine: a subgroup analysis of the ESCAPE study
title_full	The effectiveness and safety of amisulpride in Chinese patients with schizophrenia who switch from risperidone or olanzapine: a subgroup analysis of the ESCAPE study
title_fullStr	The effectiveness and safety of amisulpride in Chinese patients with schizophrenia who switch from risperidone or olanzapine: a subgroup analysis of the ESCAPE study
title_full_unstemmed	The effectiveness and safety of amisulpride in Chinese patients with schizophrenia who switch from risperidone or olanzapine: a subgroup analysis of the ESCAPE study
title_sort	effectiveness and safety of amisulpride in chinese patients with schizophrenia who switch from risperidone or olanzapine: a subgroup analysis of the escape study
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/9123e28ac8cd4abca0e9426817d86ee4
work_keys_str_mv	AT liangy theeffectivenessandsafetyofamisulprideinchinesepatientswithschizophreniawhoswitchfromrisperidoneorolanzapineasubgroupanalysisoftheescapestudy AT yux theeffectivenessandsafetyofamisulprideinchinesepatientswithschizophreniawhoswitchfromrisperidoneorolanzapineasubgroupanalysisoftheescapestudy AT liangy effectivenessandsafetyofamisulprideinchinesepatientswithschizophreniawhoswitchfromrisperidoneorolanzapineasubgroupanalysisoftheescapestudy AT yux effectivenessandsafetyofamisulprideinchinesepatientswithschizophreniawhoswitchfromrisperidoneorolanzapineasubgroupanalysisoftheescapestudy
_version_	1718401504514146304

The effectiveness and safety of amisulpride in Chinese patients with schizophrenia who switch from risperidone or olanzapine: a subgroup analysis of the ESCAPE study

Ejemplares similares